Related Experiment Videos
Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications
1Department of Medicine, University of Miami School of Medicine, Miami, FL, USA. murray.epstein@med.va.gov
Abstract:
End-stage renal disease is an enormous public health burden with an increasing incidence and prevalence. This escalating prevalence suggests that newer therapeutic interventions and strategies are needed to complement current antihypertensive approaches. Although much evidence shows that angiotensin II mediates progressive renal disease, recent evidence also implicates aldosterone as an important pathogenetic factor in progressive renal disease. Several lines of experimental evidence show that selective blockade of aldosterone, independent of renin-angiotensin blockade, reduces proteinuria and nephrosclerosis in the spontaneously hypertensive stroke-prone rat model and reduces proteinuria and glomerulosclerosis in the subtotally nephrectomized rat model (ie, remnant kidney). Although pharmacological blockade with angiotensin II-receptor blockers and angiotensin-converting enzyme inhibitors reduces proteinuria and nephrosclerosis and/or glomerulosclerosis, selective reinfusion of aldosterone restores these abnormalities despite continued renin-angiotensin blockade. Based on this theoretic construct, randomized clinical studies will be initiated to delineate the potential renal-protective effects of antihypertensive therapy using aldosterone-receptor blockade. This is a US government work. There are no restrictions on its use.
Insights
Aldosterone blockade shows promise for protecting kidneys in end-stage renal disease, reducing proteinuria and glomerulosclerosis. Further clinical studies will explore its renal-protective effects as an antihypertensive therapy.
Area of Science:
- Nephrology
- Cardiovascular Research
- Pharmacology
Background:
- End-stage renal disease (ESRD) presents a significant public health challenge with rising incidence and prevalence.
- Current antihypertensive strategies require complementary interventions to manage ESRD effectively.
- While angiotensin II is a known factor in progressive renal disease, aldosterone is increasingly implicated.
Purpose of the Study:
- To investigate the role of aldosterone in progressive renal disease.
- To evaluate the renal-protective effects of selective aldosterone blockade independent of renin-angiotensin system inhibition.
- To establish the foundation for clinical trials on aldosterone-receptor blockade for renal protection.
Main Methods:
- Experimental studies using spontaneously hypertensive stroke-prone rats and subtotally nephrectomized rats.
- Assessment of proteinuria and nephrosclerosis/glomerulosclerosis.
- Selective aldosterone reinfusion experiments to observe the restoration of renal abnormalities.
Main Results:
- Selective aldosterone blockade reduced proteinuria and nephrosclerosis in rat models.
- Aldosterone reinfusion restored renal abnormalities despite ongoing renin-angiotensin blockade.
- These findings highlight aldosterone's independent role in renal damage progression.
Conclusions:
- Aldosterone blockade, independent of renin-angiotensin blockade, demonstrates significant renal-protective effects.
- Targeting aldosterone-receptor blockade represents a potential novel therapeutic strategy for ESRD.
- Randomized clinical studies are warranted to confirm the renal-protective benefits of aldosterone-receptor blockade in antihypertensive therapy.